Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
DMAC
vs
S&P 500
DMAC
S&P 500
Over the past 12 months, DMAC has outperformed S&P 500, delivering a return of +20% compared to S&P 500's +15% growth.
Stocks Performance
DMAC vs S&P 500
Performance Gap
DMAC vs S&P 500
Performance By Year
DMAC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
DiaMedica Therapeutics Inc
Glance View
DiaMedica Therapeutics is a clinical-stage drug developer focused on treatments for serious vascular and kidney-related diseases. Its main program is a drug called DM199, a lab-made version of a natural human protein, which the company is testing for conditions such as acute ischemic stroke and preeclampsia. It does not run a drugstore or sell medicines to patients today; it is trying to turn its research into approved treatments that doctors and hospitals could use. The company’s customers, if its drugs succeed, would be hospitals, physicians, and health systems that treat acute and high-risk medical conditions. For now, DiaMedica makes money in the way most early biotech companies do: it raises capital to fund research, clinical trials, and regulatory work, and it may also use partnerships or licensing deals if it finds larger drug makers to help develop or commercialize its programs. What makes its business different is that it is built around a single scientific platform rather than a broad portfolio of products. That means the company’s value depends heavily on whether its lead drug shows clear clinical benefit and can win regulatory approval. In biotech, that kind of focused model can create large upside, but it also carries a high level of scientific and development risk.